Clinical development of a recombinant live attenuated tetravalent dengue vaccine

A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate.

Dengue virus (DENV) represents a rapidly expanding global health threat, with approximately 40% of the world’s population now living in >100 countries at risk for DENV transmission, including the United States [1, 2]. In 2010, an estimated 390 million DENV infections occurred worldwide, of which 96 million were symptomatic [3]. DENV infections produce a spectrum of clinical disease. This includ...

Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials

A recombinant live attenuated tetravalent dengue vaccine (CYD-TDV) has been shown to be efficacious in preventing virologically-confirmed dengue disease, severe dengue disease and dengue hospitalization in children aged 2-16 years in Asia and Latin America. We analyzed pooled safety data from 18 phase I, II and III clinical trials in which the dengue vaccine was administered to participants age...

Safety and Immunogenicity of Recombinant, Live Attenuated Tetravalent Dengue Vaccine (CYD- TDV) in Healthy Vietnamese Adults and Children

Background: Dengue viruses (DENV1-4) are estimated to infect 50-100 million individuals per year worldwide including an estimated 500,000 people with severe dengue who require hospitalization every year. The live, attenuated, tetravalent dengue vaccine (CYD-TDV) candidate, containing four recombinant dengue viruses (CYD14), is in clinical phase III. Methods: In an observer-blind, phase II trial...

Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.

Four serotypes of monovalent live attenuated dengue virus vaccine candidates were tested for reactogenicity and immunogenicity in 49 flavivirus non-immune adult human volunteers. The four monovalent candidates were then combined into a tetravalent formulation and given to another 10 volunteers. Neutralizing antibody seroconversion rates after a single-dose monovalent vaccination ranged from 53%...

Development of an Attenuated Live Virus Vaccine against Sheep Pox